Gynecologic clear cell cancers are among the rarest and most challenging cancers to treat. They can arise in the ovary or endometrium and often respond poorly to standard chemotherapy, especially after the disease returns. For years, patients with recurrent clear cell cancers have had limited treatment options, leaving doctors searching for more effective approaches.
New research is providing hope. A phase 2 clinical trial known as LARA evaluated a combination of two targeted cancer therapies—pembrolizumab and lenvatinib—in patients with recurrent gynecologic clear cell carcinoma. While larger studies are still needed, the results suggest that combining immunotherapy with targeted therapy may represent an important step forward for this difficult-to-treat group of cancers.
Why Clear Cell Cancers Have Been So Difficult to Treat
Clear cell cancers account for a relatively small percentage of gynecologic cancers, but they are often more resistant to treatment than other cancer subtypes.
Many patients experience disease recurrence after platinum-based chemotherapy, which is typically the first-line treatment. Once the cancer returns, response rates to additional chemotherapy have historically been low, creating a significant unmet need for new therapies.
Researchers have increasingly focused on the biology of clear cell cancers and discovered that these tumors may create an environment that helps them avoid detection by the immune system. This has led to growing interest in combining immunotherapy with drugs that target tumor blood vessels and the tumor microenvironment.
How This New Treatment Combination Works
The LARA trial combined two different cancer treatments:
- Pembrolizumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells
- Lenvatinib, a targeted therapy that blocks several growth pathways used by tumors, including those involved in blood vessel formation
Researchers believe these drugs may work particularly well together. By disrupting the tumor’s blood supply and changing the tumor environment, lenvatinib may make cancer cells more vulnerable to immune attack. Pembrolizumab can then help activate immune cells to recognize and destroy those cancer cells.
This combination has already shown success in some forms of advanced endometrial cancer, leading researchers to investigate whether it could help patients with recurrent clear cell cancers as well.
The Results Suggest a Meaningful Advance
The trial enrolled patients whose cancer had returned after previous treatment, including many who had already received anti-angiogenic therapies designed to block blood vessel growth.
The findings were encouraging.
Within the first 24 weeks of treatment:
- 40% of patients experienced measurable tumor shrinkage
- 84% achieved disease control through either tumor shrinkage or stable disease
- Responses were seen even in patients whose cancer had progressed after previous targeted therapies
Researchers also observed that some patients responded quickly, while others experienced delayed responses after several months of treatment. This suggests that the immune system may continue to become more active over time in certain individuals.
Perhaps most importantly, responses were seen in tumors that lacked many of the traditional biomarkers often associated with immunotherapy success. This raises the possibility that a broader group of patients may benefit from this approach than previously thought.
What This Could Mean for Endometrial Cancer
Although most patients in the study had ovarian clear cell cancer, a smaller group had clear cell endometrial cancer.
Clear cell endometrial cancer is an aggressive subtype that can be difficult to treat once it recurs. The results of this study add to growing evidence that immunotherapy combined with targeted therapy may play an increasingly important role in treating advanced endometrial cancers.
Researchers caution that the number of endometrial cancer patients in this trial was small, so larger studies will be needed before firm conclusions can be made. Still, the findings are consistent with the growing success of immunotherapy-based strategies in gynecologic oncology.
Side Effects Still May Occur
Like many cancer treatments, the combination was associated with side effects.
The most common included:
- High blood pressure
- Fatigue
- Diarrhea
- Mouth sores
- Loss of appetite
- Hand-foot skin reactions
Most side effects were manageable with dose adjustments and supportive care. Importantly, no treatment-related deaths were reported during the study.
Researchers emphasized that careful monitoring remains essential when using this combination.
A Promising Direction for Gynecologic Cancer Care
For patients with recurrent gynecologic clear cell cancers, treatment options have historically been limited and outcomes have often been poor. The LARA trial suggests that combining immunotherapy with targeted therapy may offer a new path forward.
While larger randomized trials are still needed, the results support the growing belief that future cancer treatment will rely not only on attacking tumors directly but also on helping the immune system recognize and fight them more effectively.
For patients with recurrent clear cell ovarian or endometrial cancer, that could represent an important step toward more effective and personalized treatment options.
Source:
Ngoi NYL, Lee JY, Lim D, et al. Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2026;27(2):201-211. Accessed by: https://ascopost.com/news/january-2026/pembrolizumab-plus-lenvatinib-in-recurrent-gynecologic-clear-cell-carcinoma/?utm_source=pushly
